Recombinant Human LILRB2 (C-6His)

Description

EnkiLife provides the Recombinant Human LILRB2 (C-6His) protein,aslo know as Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2,LIR-2,Leukocyte Immunoglobulin-Like Receptor 2,CD85 Antigen-Like Family Member D,Immunoglobulin-Like Transcript 4,ILT-4,Monocyte/Macrophage Immunoglobulin-Like Receptor 10,MIR-10,CD85d,LILRB2,ILT4,LIR2,MIR10, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2 is produced by our Mammalian expression system and the target gene encoding Gln22-His458 is expressed with a 6His tag at the C-terminus.Accession:AAH36827.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:48.57 KDa. Background:Members of the immunoglobulin-like transcript (ILT) family are activating and inhibitory immunoreceptors whose genes are located same locus that encodes killer cell Ig-like receptors (KIR). Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2 (LIR-2) is a type I transmembrane protein. LIR-2 is expressed primarily on monocytes and dendritic cells (DC). Human LIR-2 is produced as a 598 amino acino acid precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmenbrane segment, and a 116 aa cytoplasmic domain. LIR-2 binds to Classical MHCI proteins. Ligation of LIR-2 incluces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1. LIR-2 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo.